AstraZeneca provides strategy update at JP Morgan

RNS Number : 5775X

AstraZeneca PLC

14 January 2014

 



ASTRAZENECA PROVIDES UPDATE AT JP MORGAN HEALTHCARE CONFERENCE ON PROGRESS TO ACHIEVE SCIENTIFIC LEADERSHIP AND RETURN TO GROWTH

Pascal Soriot, Chief Executive Officer, AstraZeneca will today present at the JP Morgan Healthcare Conference in San Francisco, CA at 4:30 pm Pacific time. At the conference, Pascal Soriot will provide an update on the company's development pipeline and outline its strategic priorities for 2014 as AstraZeneca continues to focus on achieving scientific leadership and returning to growth.

Highlights from the presentation:

·     AstraZeneca has made good progress in accelerating and replenishing its portfolio in its three core therapeutic areas of oncology; cardiovascular/metabolic disease; and respiratory, inflammation and autoimmune diseases. AstraZeneca's late-stage pipeline now comprises 11 Phase III programmes, almost double the number of programmes a year ago, and 27 Phase II programmes. The company has also initiated trials for its cancer immunotherapy combination portfolio for which first data readouts are anticipated in 2014/2015. An updated development pipeline table is available at www.astrazeneca.com.

·     Following the acquisition of Bristol-Myers Squibb's interests in the companies' diabetes alliance - expected to complete during the first quarter of 2014 - and as the alliance's pipeline of new products is progressively launched, AstraZeneca continues to believe a return to growth should come earlier than analyst consensus currently forecasts. AstraZeneca now expects 2017 revenues to be broadly in line with 2013 revenues.

AstraZeneca will provide a more detailed update on its progress at the company's Full Year Results on Thursday, 6 February 2014.

Details of the JP Morgan Healthcare Conference webcast and how to access the presentations are available on www.astrazeneca.com/Investors and http://events.jpmorgan.com/.  

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media Enquiries

Esra Erkal-Paler                         [phone] (UK/Global)

Ayesha Bharmal                         [phone] (UK/Global)

Vanessa Rhodes                        [phone] (UK/Global)

Michele Meixell                            [phone] (US)

Jacob Lund                                 [phone] (Sweden)

Investor Enquiries

Karl Hård                                    [phone]                  mob: [phone]

Colleen Proctor                          + 1 302 886 1842                      mob: [phone]

Anthony Brown                           [phone]                     mob: [phone]

Jens Lindberg                             [phone]                     mob: [phone]

14 January 2014

- ENDS -

 

END

 

 

MSCLIFVRLAISLIS